Search
Filter Results
- Resource Type
- Article1
- Book1
- Book Digital1
- Exam Prep1
- Article Type
- Clinical Trial1
- Clinical Study1
- Controlled Clinical Trial1
- Result From
- Lane Catalog1
- PubMed1
-
Year
- Journal Title
- Arch Dermatol1
Search Results
Sort by
- Bookeditors, Mark D. Duncan, MD, Resident Physician, Department of Medicine, UCLA Medical Center, ... Show More Los Angeles, California, Lance W. Chapman, MD, MBA, Resident Physician, Department of Dermatology, UC Irvine Medical Center, Irvine, California, Minesh P. Shah, MD, MPH, Assistant Professor, Division of General Internal Medicine, University of Illinois at Chicago, Chicago, Illinois.Contents:
Cardiology
Pulmonology
Nephrology
Gastroenterology
Endocrine and metabolic disorders
Infectious diseases
Hematology and oncology
Neurology
Rheumatology
Dermatology
General medicine
Practice examination
Shelf pearls.Digital Access LWW Health Library (PA Rotations) 2016 - ArticleAlomar A, Giménez-Camarasa JM, de Moragas JM.Arch Dermatol. 1978 Sep;114(9):1316-9.Levamisole hydrochloride, a nonspecific immunostimulant, was given to 30 children with atopic dermatitis (AD) in a double-blind manner during an eight-month period. Clinical course findings, including intradermal reactions to tuberculin, candidin, and streptokinase-streptodernase; sensitization to dinitrochlorobenzene; periphal blood T- and B-lymphocytes; in vitro lymphocyte transformation with phytohemagglutinin; and serum levels of IgM, IgG, IgA, and IgE, were noted every two months. Fifteen children completed the study. Neither the clinical course nor the immunologic values showed substantial differences between the levamisole-treated and the placebo group. Our experience with levamisole in AD is disappointing.